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Background: Care pathways have become a popular tool to enhance the quality of care by improving patient
outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. We
performed a disease specific systematic review to determine how care pathways in the hospital treatment of heart
failure affect in-hospital mortality, length of in-hospital stay, readmission rate and hospitalisation cost when
compared with standard care.
Methods: Medline, Cinahl, Embase and the Cochrane Central Register of Controlled Trials were searched from 1985
to 2010. Each study was assessed independently by two reviewers. Methodological quality of the included studies
was assed using the Jadad methodological approach for randomised controlled trials, controlled clinical trials and
the New Castle Ottawa Scale for case–control studies, cohort studies and time interrupted series.
Results: Seven studies met the study inclusion criteria and were included in the systematic review with a total
sample of 3,690 patients. The combined overall results showed that care pathways have a significant positive effect
on mortality and readmission rate. A shorter length of hospital stay was also observed compared with the standard
care group. No significant difference was found in the hospitalisation costs. More positive results were observed in
controlled trials compared to randomized controlled trials.
Conclusion: By combining all possible results, it can be concluded that care pathways for treatment of heart
failure decrease mortality rates and length of hospital stay, but no statistically significant difference was observed
in the readmission rates and hospitalisation costs. However, one should be cautious with overall conclusions: what
works for one organization may not work for another because of the subtle differences in processes and
bottlenecks.
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Chronic heart failure (CHF) is a growing health problem.
About 5.7 million people suffer from CHF in the United
States [1] and approximately 5% of all acute medical
admissions are HF-related in Europe [2]. HF is a leading
cause of mortality. It has been stated that in 2006, 1 in
8.6 death certificates in the United States mentioned
heart failure [3]. It is probably the most costly chronic
disease. Its high prevalence and mortality rate places a
huge economic burden on the health-care system. The
estimated direct and indirect costs of HF in the United* Correspondence: sevalkul@gantep.edu.tr
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reproduction in any medium, provided the orStates in 2010 were $39.2 billion in total [3]. It was
reported that the cost of HF care is two times higher
than the cost of breast cancer, and three times higher
than the costs of colorectal and lymphoma cancer care
in the USA [4]. Thus, HF management is a big challenge
for today’s health-care systems, and care services for HF
need to be adjusted to reduce costs and mortality rates
without compromising the quality of patient care. Care
pathways (CPs) have become a popular tool to enhance
the quality of care by improving patient outcomes, pro-
moting patient safety, increasing patient satisfaction, and
optimizing the use of resources [5,6]. The European
Pathway Association (international not-for-profit associ-
ation) defines CPs as “a complex intervention for the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cesses for a well-defined group of patients during a well-
defined period" [7,8]. According to the European care
pathway association, defining characteristics of CPs in-
clude: (i) An explicit statement of the goals and key ele-
ments of care based on evidence, best practice, and
patients’ expectations and their characteristics; (ii) The
facilitation of communication among team members and
with patients and families; (iii) The coordination of the
care process by coordinating the roles and sequencing
the activities of the multidisciplinary care team, patients
and their relatives; (iv) The documentation, monitoring,
and evaluation of variances and outcomes; and (v) The
identification of the appropriate resources. The aim of a
care pathway is to enhance the quality of care, across
the continuum, by improving risk-adjusted patient out-
comes, promoting patient safety, increasing patient satis-
faction, and optimizing the use of resources [7].
Although CPs have been used since the 1980s, and
many high-quality articles have been published in inter-
national peer reviewed journals describing their benefits
[9,10], the effectiveness of CPs is still controversial [11-
13]. Systematic reviews and meta-analyses have received
increasingly more attention from investigators for evalu-
ating the effect of the implementation of CPs [14-16].
The results of some generic and disease-specific meta-
analyses showed that pathways are effective in improving
clinical and patient-related outcomes [14-19]. But none
of them showed a significant effect of CPs on heart fail-
ure or in hospital treatment. Therefore, in this study we
performed a disease-specific systematic review to show
recent evidence of how CPs for hospital-based treatment
of heart failure (HF) affect in-hospital mortality, length




A dual approach was used to search the literature.
Firstly, MeSH key words of "critical pathways" AND
"heart failure" AND "congestive heart failure" were
searched in Medline, Cinahl, Embase and the Cochrane
Central Register of Controlled Trials databases. Sec-
ondly, a non-MeSH approach was used based on the fol-
lowing search string: ‘clinical pathway’ OR ‘critical
pathway’ OR ‘care map’ OR ‘clinical path’ OR ‘multidis-
ciplinary approach’ AND “heart failure OR congestive
heart failure”. No limits were used except publication
year. Because the first CPs in healthcare originated in
the 1980s [20] the search was limited to years between
1985 and 2011. The authors of five relevant studies were
contacted for further information. One author provided
the original data [5]. The other authors did not reply
[21-24].Study inclusion/exclusion criteria
We included randomised controlled trials (RCTs), con-
trolled clinical trials (CCTs), controlled before-after
studies (CBAs), and interrupted time series (ITS) in the
systematic review. Studies were considered randomised
when it was specifically stated in the text. All of the
included studies compared the care provided through
CPs with standard medical care. Studies were included
when at least one of the following outcome indicators
had been evaluated: hospital mortality rate, rate of re-
admission, length of hospital stay (the number of days of
acute hospitalisation from admission to discharge) and
hospitalisation costs (total cost of acute hospitalisation).
Articles that were strictly descriptive (study protocols,
review articles and theoretical articles), articles with no
control group, articles that did not assess at least one of
the four outcomes and articles for which the relevant in-
formation could not be retrieved were excluded. “Only
studies which met the care pathways definition of EPA
were included [8]. For this purpose a specific checklist
has been developed to analyze the papers (Additional file
1: Annex 1). The papers that met at least 5 or 6 criteria
have been included in the study (Additional file 1:
Annex 2). All of the excluded articles and exclusion rea-
sons were given in the Additional file 1.
Outcome measures
In this study, results were combined according to four
outcome indicators: hospital mortality rate, rate of re-
admission, length of hospital stay (the number of days of
acute hospitalisation from admission to discharge) and
hospitalisation costs (total cost of acute hospitalisation)
to evaluate the overall effect of CPs on HF. These were
the most commonly used and available outcomes in the
included studies.
Data extraction and quality assessment
The author, the publication year, the sample size, the
characteristics of the population studied (age, sex, race,
primary diagnosis, etc.), study design, type of control
and outcome measures were recorded. Two reviewers
independently screened the titles, abstracts and key-
words to determine eligibility and assess methodological
quality of the included studies and record the findings.
The reviewers were blinded to the names of the authors,
the institution where the study had been carried out,
and the journal. Any disagreement was discussed with a
third reviewer. Methodological quality of the included
studies was evaluated using the Jadad methodological
approach for RCTs and CCTs and the New Castle Ot-
tawa Scale for interrupted time series [25,26]. All the
studies that met the inclusion criteria (see above) but
did not include any items of the checklists were
excluded.
Figure 1 Flowchart of the selection of the studies.
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using percentages given in the articles. If an article only
reported confidence intervals instead of standard devia-
tions, standard deviations were calculated via the confi-
dence interval formula (mean± 1,96SE). Also, some
results not described in text or tables but shown in graphs
were extracted from the graphs by using data extraction
software with the mean and confidence intervals given in
the graph (XY data extraction software version 4.1).
Data analysis
The primary meta-analyses were performed according to
the guidelines set out by the Cochrane Collaboration
regarding statistical methods [26]. For dichotomous vari-
ables, risk ratios (RR) and 95% confidence intervals (95%
CI) were calculated using standard care group as the
reference group. For the meta-analysis of continuous
variables, the Weighted Mean Difference (WMD) with
95% CI was used. Since different kinds of study design
were combined and the sample sizes of included studies
were different, a ‘random effects model’ was used for all
the outcomes [27]. In order to compare CPs with usual
care, the costs were measured in United States dollars
(US$) divided by 10,000 and expressed as the Weighted
Mean Difference (WMD). One of the three included
studies reported the costs in Euro (€)[10]. These costs
were converted to US dollars ($) using the official ex-
change rate of the year of study data (year 2004). The
costs were adjusted for the inflation rate in the United
States and actualised to year 2004. Sensitivity analysis
was performed to identify studies with a low quality [27].
For each outcome, meta analyses were repeated many
times to check the robustness of findings using different
assumptions. The largest, the smallest, the earliest
studies and the studies with the most different results
were excluded respectively to see the effect on the
results. These sensitivity analysis results are given in
the Additional file 1. In addition to sensitivity analyses, po-
tential publication bias was assessed using a funnel plot
which is a scatter plot of the estimate of the effect from
each study in the meta-analysis against a measure of its pre-
cision, usually 1/SE [27]. The results for each outcome
measure were presented separately for different study types.
The results for each outcome measure were presented
separately for different study types with forest plots.
Analyses were performed using the Review manager
software package (RevMan), version 5.0 and a P-value
smaller than 0.05 was considered to be statistically
significant.
Results
Description of the studies
The search strategy resulted in a total of 7981 records
(6553 irrelevant, 1382 duplicated). Among 46 studiesidentified, only 7 publications met the study inclusion
criteria [5,10,22,23,28-30] and they were included in the
systematic review for a total sample of 3,690 patients,
as shown in Figure 1. This systematic review consists
of three randomised controlled trials [11,22,23] one
interrupted time series [5] and three controlled studies
[28-30].
Summary of included study characteristics were given
in Table 1. Two publications reported results of studies
with a multi-centre design, whereas five were single-
centre studies. Two studies were based in Italy, four in
the USA, one in Canada. The setting characteristics of
the studies (hospital size, urban/rural typology, educa-
tion, living conditions) were not fully reported.Effect of CPs: mortality rate
Five studies were included in the systematic review
(three randomised controlled, two controlled studies) to
estimate the pooled risk ratio for mortality of the care
pathway group compared to standard care. A total of
2,343 patients were analysed, including 1206 patients in
the care pathway and 1137 patients in the standard care
groups. The use of CPs had a significant positive effect
in 2 of 5 studies, including the mortality rate [5,10].
Also, in the other three studies, the mortality rate
decreased in the care pathway group, albeit not signifi-
cantly [22,23,29]. Risk ratio (RR) estimates and their 95%
confidence intervals are shown in Figure 2. The overall
result of combining the RCTs was not statistically sig-
nificant. The pooled risk ratio for mortality was 0.45,
95%CI= 0.21-0.94, P= 0.03.
Table 1 Summary of included study characteristics
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demographics
Main outcome NYHA





Prospective 14 hospitals located
in four Italian
regions, Italy
19 429 47,7 51,2 81,7 79,7 Gender, age, severity
at admission,
co-morbidities
In-hospital mortality, length of stay,







Prospective 10 Hospitals in
Newyork, the USA
9 1504 49 48 77 74 Gender, age, race,
insurance, medication
use at admission
In-hospital mortality, length of stay,


















Prospective Italian hospital, Italy 12 246 43,62 - 78,9 - Gender, age In-patient mortality, length of stay,
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12 754 42 50 75,8 74,39 Gender, age,
co-morbidities




















Figure 2 Forest plot of comparison for rate of hospital mortality.
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We included in the systematic review 5 studies reporting
risk estimates for readmission rate [5,10,22,29,30]. A
total of 3,006 patients were analysed, including 1508
patients in the care pathway and 1498 patients in the
standard care groups. Figure 3 displays the result of the
primary meta-analysis. One of the studies found that the
risk of readmission significantly decreased in the care
pathway group [10]. The overall RR for RCTs was 0.79,
95% CI = 0.49-1.27, P = 0.33. The overall result of meta-
analysis was significant (RR = 0.81, 95%CI= 0.66-0.99,
P= 0.04).
Effect of CPs: LOS
Five studies were included in the systematic review (one
randomised controlled, four controlled studies) repre-
senting a study population of 2,095 patients. Examining
the effect of CPs on the length of stay, out of five studiesFigure 3 Forest plot of comparison for rate of readmission.[5,10,28-30] three studies showed a significantly shorter
LOS in the care pathway group [5,28,30]. The overall
results of the random-effects model showed that care
pathway provided a positive reduction in LOS when
compared with the standard care (WMD=−1.89, 95%
CI= (−2.44-(−)1.33 days, P < 0.001) (Figure 4).
Effect of CPs: hospitalisation costs
Three of the included studies (one randomised con-
trolled, two controlled), representing a study population
of 1776 patients, reported costs during hospitalisation
[10,28,30]. Two of the CCTs [28-30] found significantly
high hospitalisation costs for the care pathway groups.
Also, the combined result of the controlled studies was
significant (WMD= (−)2.35, 95%CI= (−)4.11-(−)0.58,
P < 0.009) but the RCT was not (WMD= (−)0.11, 95%
CI= (−)0.25-0.03, P= 0.11). Overall, the meta analysis
results of the random effects model did not show any
Figure 4 Forest plot of comparison for length of hospital stay.
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CPs were compared with the non-pathway based care, as
shown in Figure 5 (WMD= (−)1.57, 95%CI= (−)3.66-
0.52, P= 0.14).Discussion
In this systematic review, the results of 7 publications
which met the study inclusion criteria were combined to
determine the effect of CPs on the outcomes of in-
hospital treatment for heart failure: in-hospital mortality,
rate of readmission, LOS and hospitalisation costs.
This study is the first systematic review to show an
impact of CPs on the treatment of heart failure.
The primary finding of this systematic review was that
the implementation of CPs for heart failure reduced hos-
pital mortality and length of stay without increasing hos-
pitalisation costs. Also readmission rate decreased in the
care pathway groups (Figure 3). By looking at this data,
it is evident that CPs can effectively improve the quality
of care provided to patients suffering from heart failure.
Lower mortality rates and shorter hospital stays among
CP patients are associated with standardisation of the careFigure 5 Forest plot of comparison for hospitalisation cost.process. However, we must be careful with the overall
conclusions: pathways are not just documents recorded
in the patient charts but a way to organize and standard-
ise a multi-disciplinary care for patient groups using
well-known quality improvement methodologies [31].
In the included studies, all patients were admitted to
hospital with a primary diagnosis of chronic heart fail-
ure. The definition of readmission rate was different in
the included studies. In two studies, readmission was
recorded within 31 days after discharge [5,10]; in one
study it was recorded within 90 days of discharge[30]
and in two studies 6 months after hospital discharge
[27,29]. For all included studies cost was calculated for
hospital stay per-patient but no additional information
was given about the cost calculation.
There are two previous generic meta-analysis reports
suggesting that implementation of CPs can achieve a re-
duction in some of the patient outcomes [18,19]. Al-
though some of the findings were confirmed by our
study, there are also several reasons that preclude com-
parison of our findings with generic meta-analyses.
Firstly, pathways are a learning tool both at professional
(individual) and organizational (team) level [32], and
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tasks to be learned, which affects performance of path-
ways and also patient outcomes. Also most of the out-
comes such as mortality rate, readmission rate, LOS and
costs of hospitalisation are related to types of treatments
given to patients and show differences among specific
patient groups. Different interventions are sometimes
classified under the same term. When different clinical
topics are included in the meta-analysis, the effect size
of the intervention mostly shows huge variations be-
tween pathways for different patient groups. Exploring
the reasons behind the heterogeneity rather than deriv-
ation of a single summary estimate of the effect size has
emerged as the main goal of the meta-analysis [33].
Some statistics which were estimated for general popula-
tions from the generic meta-analysis such as weighted
mean difference, OR or RR cannot be extrapolated to
any patient group.
This systematic review has some limitations. We ini-
tially identified 46 relevant studies among 7981 total
search results. However, only 7 studies could be consid-
ered as CPs and met our inclusion criteria. The scarcity
of publications on CP probably results from the fact that
CPs have only recently become a popular tool and the
associated benefits for heart failure interventions are still
not clear. Therefore, not many studies could be included
to evaluate the effect of CPs on in-hospital treatment of
heart failure.
In this systematic review, we observed that the find-
ings of controlled trials were always more positive than
the RCTs. In the included papers all of the study groups
were experimental and the data was collected prospect-
ively. Among included studies, three were randomized
controlled clinical trials and one of them was an inter-
rupted time series. In this study, measurements were
performed on the same patients before and after the ex-
periment, so patient characteristics are unlikely to have
affected the outcomes. But 3 of the included studies
were non-randomised; and historical controls were used.
In the non-randomised studies, differences in patient
characteristics may have affected the outcomes. Al-
though patient characteristics were similar in the study
and control groups (Table 1), differences in patient char-
acteristics may explain more positive results in CCTs.
Moreover, none of the studies mentioned in-hospital
complications; thus, the association between hospital
complications, costs and LOS could not be addressed. In
addition, we assume that combining clinical indicators
with a satisfaction survey could have given a more ac-
curate measure of the true level of quality achieved
through CPs [34]. Concerning included studies, only two
studies measured patient satisfaction score [10,23] and
reported no significant effect. As studies used different
quality assessment tools, combining of results was notpossible; so, patient satisfaction scores were not included
in the systematic review as an outcome.
Since heart failure is defined in different ways and in-
clusion criteria can vary from study to study, individual
patient data meta-analysis would have been a good op-
tion to overcome some of the shortcomings of our ana-
lysis. The New York Heart Association classification
would have been used to perform subgroup analysis. Un-
fortunately only four of the seven studies reported
NHYA classification and they did not provide separate
results for each classification. Another limitation of our
study was that despite performing a search from 1985 to
2011, we could not identify any eligible study until 1999.
Thus, we cannot generalise our results for the last
26 years but our study results are valid for the last
13 years.
In 6 studies [5,10,23,28-30], pathway and control
groups were well-balanced with regard to the number of
the patients, and in 5 studies [5,10,22,29,30] pathway
and control groups were age- and sex-matched. More-
over, these five studies were similar with respect to the
age and sex ratio (female/male) of the patients. One
study did not provide patient characteristics [28] and
one study enrolled only female patients [23]. The title of
this study suggests that the study sample consists of
older women, but the mean age of the patients was simi-
lar to the other studies included.
Although the above mentioned patient characteristics
of the studies were similar, we observed a high hetero-
geneity in the statistical analysis by use of the I2 statistic,
which was introduced by Higgins et al. [27]. Although I2
values of 75% were described as high [27], no desired
threshold for I2 was determined. Recently it was men-
tioned that heterogeneity is to be expected in a meta-
analysis because studies are performed by different
teams in different settings [34]. Using a random-effects
model to reduce the effect of heterogeneity on a statis-
tical analysis is a widely used approach [27]. In addition,
it is known that sensitivity analysis should be accompan-
ied by an analysis to show the effect of heterogeneity on
statistical analysis [35]. A risk of bias check list has been
developed according to pre-defined inclusion criteria
and papers were ranged according to the risk of bias for
each outcome. Results of the sensitivity analysis were
given in the Additional file 1. In sensitivity analysis, rela-
tive risks were similar for in-hospital mortality, re-
admission rate and length of stay. A significantly greater
mean difference was observed for hospitalization cost
which is probably a consequence of the small number of
studies included for this outcome.
There is an international controversy on the definition
of pathways [36-38]. Vanhaecht et al. defined 17 criteria
[39] and the paper by De Bleser et al. gave a detailed
overview on how a definition of pathways could be built
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their paper, consisting of five criteria for care pathways
based on the aforementioned papers previously pub-
lished [37]. Both criteria are valid and usable. In this
study only studies meeting the CPs definition of EPA,
which covers Kinsman et al. criteria’s, were included in
this systematic review [6].
According to the definition, pathways describe patient
processes and in the planning of a pathway, identifica-
tion, and resolution of process ‘bottlenecks’ frequently
occur. However, what works for one organization may
not work for another, because of subtle differences in
these processes and bottlenecks. Organizations are also
different in their readiness for and capacity to change.
These are often referred to as context issues, which in-
fluence implementation and effectiveness [40]. Hawe,
Shiell, and Riley (2004) suggested as a possible solution
to standardize complex interventions, the function and
process of the intervention and not only the components
[41]. This information on the context and the change
process is critical to the ability of others to adapt the
findings of a study to their own setting [40,42]. A path-
way which works in one place may be ineffective in an-
other without this key knowledge. In our opinion, this
important issue did not affect the validity of our find-
ings. In fact, all the papers that have been selected in
our review included process and outcome indicators that
provided data to understand if pathways worked (Add-
itional file 1: Annex 2). Therefore we think that our
paper addresses the research question adequately and we
also think that our findings are based on consistent data.
A final remark is that the literature suggests that when
researchers implement a pathway in a team that is
already performing well, one may not identify significant
improvements. A poorly performing team may, on the
other hand, be greatly improved by the implementation
of a new pathway, but these teams may not always be
interested in improving the organization of their care
process [31]. Pathways are one of the tools interdiscip-
linary teams can use to audit, standardise and improve
the organisation of care.
Conclusion
Our goal was to demonstrate the impact of care path-
ways on patient outcomes. By combining all possible
results of care pathways, it can be concluded that care
pathway for heart failure treatment showed a decreased
mortality rate and length of hospital stay, but no statisti-
cally significant difference was observed in the readmis-
sion rates and hospitalisation costs. Although some
findings of this systematic review showed that care path-
ways have a positive effect on some outcomes, one
should consider the limitations of this study while inter-
preting the results. In the future, a meta-analysis shouldbe performed with an increased number of included
studies to decrease heterogeneity of study designs. We
suggest that the findings and possible limitations of this
study be considered in the planning of future meta-
analyses to shed light on the effect of pathways in spe-
cific patient groups.
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